Literature DB >> 17000962

Baseline MRI predicts future attacks and disability in clinically isolated syndromes.

M Tintoré1, A Rovira, J Río, C Nos, E Grivé, N Téllez, R Pelayo, M Comabella, J Sastre-Garriga, X Montalban.   

Abstract

OBJECTIVE: To determine the relation between baseline MRI and both conversion to multiple sclerosis (MS) and development of disability in a cohort of patients with clinically isolated syndromes (CIS).
METHODS: From 1995 to 1998, 175 consecutive patients with CIS underwent brain MRI within 3 months of their first attack and again 12 months and 5 years later. We studied the number and location of lesions at baseline and development of new T2 lesions. We also analyzed conversion to MS and development of disability (Expanded Disability Status Scale [EDSS] > or = 3.0).
RESULTS: We included 156 patients with CIS followed for a median of 7 years. Compared to the reference group with 0 Barkhof criteria at baseline MRI, patients with one or two Barkhof criteria showed an adjusted hazard ratio (HR) of 6.1 (2.2 to 16.6) and patients with three to four Barkhof criteria of 17.0 (6.7 to 43) for conversion to MS and differentiated patients with low, medium, and high conversion risk. EDSS at year 5 correlated with baseline number of Barkhof criteria (r = 0.46, p < 0.0001). When categorizing by number of baseline lesions, similar results were seen. Patients with a baseline MRI with three to four Barkhof criteria had an adjusted HR of 3.9 (1.1 to 13.6) for reaching EDSS > or = 3.0. Only 10% of the latter had disability at year 5, but 40% reached this at 8 years.
CONCLUSIONS: Baseline MRI determines the risk for converting to clinically definite multiple sclerosis and correlates with disability at 5 years. The proportion of patients developing disability is low during the first 5 years but rapidly increases shortly after.

Entities:  

Mesh:

Year:  2006        PMID: 17000962     DOI: 10.1212/01.wnl.0000237354.10144.ec

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  63 in total

Review 1.  The radiologically isolated syndrome: take action when the unexpected is uncovered?

Authors:  Johann Sellner; Lucas Schirmer; Bernhard Hemmer; Mark Mühlau
Journal:  J Neurol       Date:  2010-05-26       Impact factor: 4.849

Review 2.  Rationale for early intervention with immunomodulatory treatments.

Authors:  Mar Tintoré
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

3.  A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS.

Authors:  Marco Rovaris; Elda Judica; Antonia Ceccarelli; Angelo Ghezzi; Vittorio Martinelli; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

Review 4.  [Clinically isolated syndrome].

Authors:  M Platten; T Lanz; M Bendszus; R Diem
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

Review 5.  [Choice of early and escalation treatment options for multiple sclerosis].

Authors:  R A Linker; B C Kieseier
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

6.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Authors:  Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani
Journal:  Int J MS Care       Date:  2012

Review 7.  Managing MS in a changing treatment landscape.

Authors:  Martin Duddy; Aiden Haghikia; Eleonora Cocco; Christian Eggers; Jelena Drulovic; Olga Carmona; Helene Zéphir; Ralf Gold
Journal:  J Neurol       Date:  2011-03-25       Impact factor: 4.849

8.  Differential diagnosis of suspected multiple sclerosis: a consensus approach.

Authors:  D H Miller; B G Weinshenker; M Filippi; B L Banwell; J A Cohen; M S Freedman; S L Galetta; M Hutchinson; R T Johnson; L Kappos; J Kira; F D Lublin; H F McFarland; X Montalban; H Panitch; J R Richert; S C Reingold; C H Polman
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

9.  The diagnosis of multiple sclerosis and the clinical subtypes.

Authors:  Barrie J Hurwitz
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

10.  Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage.

Authors:  Ralf A Linker; Peter Brechlin; Sarah Jesse; Petra Steinacker; D H Lee; Abdul R Asif; Olaf Jahn; Hayrettin Tumani; Ralf Gold; Markus Otto
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.